Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Pulmagen Therapeutics SynergyfiledCriticalAstrazeneca Ab
Priority to CR11790ApriorityCriticalpatent/CR11790A/en
Publication of CR11790ApublicationCriticalpatent/CR11790A/en
La invención proporciona los compuestos nombrados de fórmula (I), en la que R4 es una quinuclidina N-sustituida (I), composiciones farmacéuticas que los continen y un proceso para preparar las composiciones farmacéuticas.The invention provides the named compounds of formula (I), wherein R 4 is an N-substituted quinuclidine (I), pharmaceutical compositions that continue them and a process for preparing pharmaceutical compositions.
CR11790A2010-11-122010-11-12
QUINUCLIDINE DERIVATIVES AS M3 MUSCARINIC RECEPTORS ANTAGONISTS
CR11790A
(en)
Compounds derived from n-substituted benzamides or n-substituted pyridinamides; pharmaceutical composition that includes them; treatment method; and its use for the treatment of selected diseases or disorders of pain, depression and cardiovascular, respiratory or psychiatric diseases or combinations thereof.
DERIVATIVES OF PIRIDIL-PROLINAMIDE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND ITS USE FOR THE TREATMENT OF ANXIETY, DEPRESSION AND DISORDERS OF THE SOUND.